Business Context and Reporting Period
This Form 10-K covers the fiscal year ended December 31, 2009, for Spatializer Audio Laboratories, Inc. (Note: The input metadata references "Enveric Biosciences," but the filing text explicitly identifies the registrant as Spatializer Audio Laboratories, Inc.). The Company is currently a shell corporation with no active operations. It sold substantially all of its intellectual property assets and its subsidiary, Desper Products, Inc., to DTS, Inc. on July 2, 2007. Following the sale, the Company distributed remaining cash assets to shareholders in April 2008 and has since had no revenue-generating activities.
Key Financial Metrics
| Metric | 2009 | 2008 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(58,544) | $(143,636) |
| Operating Expenses | $55,569 | $151,441 |
| Cash and Cash Equivalents (Year End) | $1,792 | $66,833 |
| Working Capital | $(10,075) | $48,469 |
| Total Assets | $1,792 | $69,675 |
| Total Liabilities | $11,867 | $21,206 |
| Stockholders' Equity | $(10,075) | $48,469 |
Debt and Liquidity: The Company has no long-term debt. Current liabilities consist primarily of accounts payable ($11,867). Liquidity is critically low, with cash reserves of less than $2,000 as of year-end.
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately 59% from $143,636 in 2008 to $58,544 in 2009. This improvement was driven by a 63% reduction in operating expenses (from $151,441 to $55,569) due to the suspension of operations.
- Cash Depletion: Cash and cash equivalents declined by 97%, dropping from $66,833 in 2008 to $1,792 in 2009. The Company utilized cash to fund general and administrative expenses.
- Working Capital Deficit: The Company moved from positive working capital of $48,469 in 2008 to a negative working capital position of $(10,075) in 2009.
- Interest Income: The Company earned $12,684 in interest income in 2008, which dropped to $0 in 2009 as cash balances were depleted.
Outlook, Risks, and Management Commentary
Going Concern Uncertainty: The independent auditors have issued a report stating that the Company's circumstances raise substantial doubt about its ability to continue as a going concern. The financial statements do not include adjustments that might result from the outcome of this uncertainty.
Future Strategy: Management's current policy is to retain earnings (if any) to maintain reporting status and potentially sell the Company as a shell corporation or merge it with a new operating business. No specific business model or funding source has been revealed for new operations.
Risks:
- No Revenue Source: The Company has no means to generate revenue.
- Liquidity Risk: Without outside funding, the Company cannot maintain its liquidity position.
- Stock Volatility: The stock trades on the OTC Bulletin Board with low volume and high volatility.
- Dilution: Any future financing to pursue new opportunities is likely to dilute existing stockholders.
Subsequent Events: In January and February 2010, the President and CFO loaned the Company a total of $32,500 to fund operations.
Investor Verification Checklist
- Verify Company Identity: Confirm the registrant is Spatializer Audio Laboratories, Inc., not Enveric Biosciences (metadata discrepancy).
- Cash Runway: Assess the sufficiency of the $1,792 cash balance against ongoing administrative costs and the $32,500 in related-party loans.
- Shell Status: Confirm the Company's intent to operate as a shell for a reverse merger or acquisition, as no organic business exists.
- Related Party Transactions: Review the $32,500 loans from officers and the ownership concentration (directors and officers own ~35% of shares).
- Accounting Disagreements: Note the history of disagreements with auditors regarding development stage classification and stock valuations in 2009.